Trials
2 active
5 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Administration of 90 mg sonlicromanol (100 mg sonlicromanol.HCl) twice daily during 52 weeks”In the company’s words, NCT06451757 on ClinicalTrials.gov
- Tested for
- Mitochondrial Diseases, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS), Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation
- Main trialPhase 3
- “The KHENERFIN study aims to determine whether the study medicine, sonlicromanol, is able to reduce symptoms of fatigue and the impact of fatigue on daily life, and whether sonlicromanol is able to improve physical abilities of people like balance control and lower limb skeletal muscle strength in people with mitochondrial disease. In this study, the effects of sonlicromanol are compared against a placebo, a tablet identical in appearance and taste but without the active drug. Participants take either sonlicromanol or placebo twice daily for a treatment duration of 52 weeks. In addition to…”In the company’s words, NCT06451757 on ClinicalTrials.gov
- Other names
- KH176
Other drugs for Mitochondrial Diseases
- NomlabofuspLarimar Therapeutics, Inc. · Phase 3
- OmaveloxoloneBiogen · Phase 3
- SepofarsenLaboratoires Thea · Phase 3
- VatiquinonePTC Therapeutics · Phase 3
- DichloroacetateSaol Therapeutics Inc · Phase 3
- DT-216P2Design Therapeutics, Inc. · Phase 1/2
Coming up1
- Sep 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Sep 2029 | KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases | |
| Phase 2Completed | 24 May 2022 | The KHENERGYZE Study | |
| Phase 2Suspended | 1 Dec 2025 | The KHENERGYC Study | |
| Phase 1Completed | Sep 2015 | A Dose-escalating Clinical Trial With KH176 | |
| Phase 2Authorised | not given | SON4PEM study: Sonlicromanol in post-COVID: A randomized, double-blind, placebo-controlled, phase II trial |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026